Publication in Nature Communications validates BiomX's phage therapy platform showing positive trial results.

A premier research journal article validates BiomX’s phage therapy platform with Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infections, showing a 2.7 log₁₀ reduction compared to placebo, no resistance, and preservation of a healthy microbiome. BiomX is moving forward with its Phase 2b trial of BX004, expecting results in Q1 2026. The publication highlights the effectiveness of BX004 in reducing bacteria in CF patients, with no resistance and positive microbiome changes. The study demonstrates the success of BiomX’s approach in developing bacteriophage therapies for chronic diseases. BiomX’s BX004 achieved a significant improvement in bacterial reduction compared to placebo in CF patients, with no resistance and positive microbiome changes. The study illustrates the effectiveness of large-scale data analysis in optimizing bacteriophage cocktails for treating chronic infections related to cystic fibrosis. BiomX’s Phase 1b/2a study of BX004 showed a 2.7 log₁₀ reduction in bacterial load compared to placebo, with successful bacterial reduction, no treatment-related resistance, and favorable shifts in microbiome composition post-treatment. The Nature Communications publication showcases the full translational path from laboratory discovery to clinical testing of BX004, demonstrating its effectiveness in treating chronic pulmonary infections caused by P. aeruginosa in CF patients. BiomX is leading the development of natural and engineered phage cocktails and personalized treatments for chronic diseases with significant unmet needs, with BX004 receiving FDA Fast Track and Orphan Drug Designations.

Read more at GlobeNewswire: BiomX Announces Publication in Nature Communications of